Rocket Pharmaceuticals (RCKT) closed at $2.30 on November 13, 2026, down 3.8% from the previous close, on volume of 1,659,350 shares (30-day average 1,859,045).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
Rocket Pharmaceuticals (RCKT) Receives a Hold from Leerink Partners
TipRanks (Fri, 13-Nov 9:40 AM ET)
Canaccord Genuity Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)
TipRanks (Fri, 13-Nov 9:06 AM ET)
Rocket Pharmaceuticals (RCKT) Gets a Buy from Needham
TipRanks (Fri, 13-Nov 9:06 AM ET)
Rocket Pharmaceuticals (RCKT) Gets a Buy from Wedbush
TipRanks (Fri, 13-Nov 8:56 AM ET)
Rocket Pharmaceuticals GAAP EPS of -$0.43 misses by $0.03
Seeking Alpha News (Thu, 12-Nov 4:24 PM ET)
Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress
Business Wire (Thu, 12-Nov 4:00 PM ET)
Cantor Fitzgerald Sticks to Its Buy Rating for Rocket Pharmaceuticals (RCKT)
TipRanks (Tue, 10-Nov 7:55 AM ET)
Rocket Pharmaceuticals to Participate in Chardan's 10th Annual Healthcare Conference
Business Wire (Thu, 15-Oct 7:00 AM ET)
Business Wire (Wed, 7-Oct 9:36 AM ET)
Business Wire (Tue, 6-Oct 4:12 PM ET)
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Rocket Pharmaceuticals trades on the NASDAQ stock market under the symbol RCKT.
As of November 13, 2026, RCKT stock price declined to $2.30 with 1,659,350 million shares trading.
RCKT has a beta of 2.40, meaning it tends to be more sensitive to market movements. RCKT has a correlation of 0.16 to the broad based SPY ETF.
RCKT has a market cap of $252.48 million. This is considered a Small Cap stock.
Last quarter Rocket Pharmaceuticals reported $0 in Revenue and -$.43 earnings per share. This fell short of revenue expectation by $-445,456 and missed earnings estimates by -$.03.
In the last 3 years, RCKT traded as high as $32.53 and as low as $2.17.
The top ETF exchange traded funds that RCKT belongs to (by Net Assets): VTI, IWM, VXF, FESM, IWN.
RCKT has underperformed the market in the last year with a price return of -27.4% while the SPY ETF gained +13.4%. RCKT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -31.1% and -5.7%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
RCKT support price is $2.28 and resistance is $2.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RCKT shares will trade within this expected range on the day.
